A person’s MTHFR gene type significantly affects how well folic acid works to lower homocysteine and improve heart health. According to Gram Research analysis of 344 patients, those with the CC gene version had an 81.6% success rate in reaching their homocysteine targets, while those with the TT version had much lower success rates. Genetic testing could help doctors predict individual treatment response and adjust folic acid doses accordingly.
A new study of 344 patients reveals that a common genetic variation affects how well folic acid supplements work to lower homocysteine, a substance linked to heart disease. Researchers found that people with different versions of the MTHFR gene responded differently to folic acid treatment. Those with the CC gene version had the best results, with over 81% reaching their treatment goals within a year. People with the TT version had much lower success rates. This discovery suggests doctors might one day use genetic testing to predict which patients will benefit most from folic acid therapy and adjust their treatment plans accordingly.
Key Statistics
A 2026 study of 344 patients with high homocysteine found that those with the CC MTHFR gene version had an 81.6% success rate in reaching their treatment targets with folic acid, compared to significantly lower rates in patients with the CT or TT gene versions.
Patients with the TT MTHFR genotype were 92% less likely to achieve their homocysteine treatment targets with standard folic acid therapy compared to those with the CC genotype, according to a 2026 analysis of 344 patients tracked over 12 months.
Blood vessel stiffness, measured by pulse wave velocity, decreased significantly in all MTHFR genotype groups receiving folic acid treatment over 12 months, with the most improvement observed in patients with the CC genotype.
A 2026 study of 344 patients demonstrated that MTHFR C677T genetic variation independently predicted folic acid treatment success, with CT and TT genotypes showing 68% to 92% lower odds of reaching homocysteine targets compared to the CC genotype.
The Quick Take
- What they studied: Whether a person’s genetic makeup affects how well folic acid supplements lower homocysteine levels and improve blood vessel function in people with high homocysteine.
- Who participated: 344 patients with elevated homocysteine levels who were genotyped for a specific genetic variation called MTHFR C677T. The group included 141 people with CC genes, 169 with CT genes, and 34 with TT genes.
- Key finding: Patients with the CC gene version had an 81.6% success rate in reaching their homocysteine treatment targets, while those with the TT version had significantly lower success rates. All groups improved over 12 months, but the genetic difference was substantial.
- What it means for you: If you have high homocysteine and take folic acid, your genes may influence how well the treatment works for you. Genetic testing might help doctors predict your response and adjust your dose or treatment plan. However, this is still emerging science, and you should discuss personalized approaches with your doctor.
The Research Details
This was a retrospective study, meaning researchers looked back at medical records of 344 patients who already had high homocysteine and had been treated with folic acid. They divided patients into three groups based on their MTHFR gene type: CC, CT, or TT. The researchers measured homocysteine levels and blood vessel function at the start of treatment and then again at 2, 4, and 12 months to track how well the treatment worked over time.
The study used statistical methods to compare how each genetic group responded to folic acid. They also looked at blood vessel health using two measurements: pulse wave velocity (how fast blood pressure waves travel through arteries) and ankle-brachial index (a comparison of blood pressure in the leg versus the arm). These measurements help doctors understand if blood vessels are working properly.
The researchers used advanced statistical analysis to determine whether genetic differences were truly responsible for the different treatment responses, accounting for other factors that might affect the results.
Understanding how genes affect medication response is important because it helps explain why some people benefit greatly from a treatment while others see little improvement. This type of research supports personalized medicine, where doctors can tailor treatments based on individual genetic profiles. If genetic testing can predict folic acid response, doctors could identify patients who need higher doses, different medications, or more frequent monitoring.
This study has several strengths: it included a reasonably large sample size of 344 patients, tracked participants over a full year, and used objective measurements of both homocysteine levels and blood vessel function. The researchers used appropriate statistical methods for analyzing repeated measurements over time. However, the study was retrospective, meaning it relied on existing medical records rather than following patients forward in a controlled way. The TT group was relatively small (34 patients), which makes conclusions about this group less certain. The study was conducted in a single healthcare system, so results may not apply equally to all populations.
What the Results Show
All three genetic groups showed improvement in homocysteine levels and blood vessel function over the 12-month treatment period. Homocysteine concentrations decreased significantly in all groups, and blood vessel stiffness (measured by pulse wave velocity) also improved. However, the degree of improvement differed substantially by genetic type.
Patients with the CC gene version had the best outcomes. Over 81% of CC patients reached their target homocysteine levels, compared to much lower rates in the other groups. The CT group had intermediate success, and the TT group had the lowest success rate. This pattern held true even after researchers accounted for other factors that might influence treatment response.
Blood vessel function improved in all groups, but the improvement was most pronounced in patients with the CC genotype. The ankle-brachial index, which measures blood flow to the legs, increased in all groups, suggesting better circulation. These improvements in blood vessel function are important because they suggest reduced cardiovascular risk.
The statistical analysis showed that genetic type was an independent predictor of treatment success, meaning the genetic difference mattered even when other variables were considered. Patients with better folate metabolism capacity (the ability to process folate efficiently) had better outcomes, which makes biological sense since folic acid must be converted to an active form to work.
The study found that blood vessel stiffness decreased over time in all groups, with the most improvement seen in the first 4 months of treatment. After 4 months, improvements continued but at a slower rate. This suggests that folic acid treatment has relatively quick effects on blood vessel function, which is encouraging for patients starting therapy.
The researchers also found that higher baseline folate metabolism capacity predicted better treatment outcomes. This suggests that people whose bodies are naturally better at processing folate may respond more favorably to supplementation. Additionally, the study confirmed that homocysteine reduction and blood vessel improvement occurred together, supporting the theory that lowering homocysteine helps protect cardiovascular health.
Previous research has suggested that MTHFR genetic variations affect how people process folate and respond to folic acid supplements. This study provides concrete evidence in a specific patient population with high homocysteine. The findings align with earlier research showing that the TT genotype is associated with lower enzyme activity, which would explain reduced folic acid effectiveness. However, this is one of the first studies to systematically track both homocysteine levels and blood vessel function across different MTHFR genotypes over an extended period.
The study was retrospective, relying on existing medical records rather than prospectively following patients, which can introduce bias. The TT genotype group was small (only 34 patients), making it harder to draw firm conclusions about this group. The study did not include a control group that didn’t receive folic acid, so we cannot definitively say the improvements were due to the treatment rather than other factors. The research was conducted in a single healthcare system, so results may not apply equally to different populations or ethnic groups. The study did not examine whether higher folic acid doses might overcome the genetic disadvantage for TT patients. Additionally, the study measured homocysteine and blood vessel function but did not track actual cardiovascular events like heart attacks or strokes.
The Bottom Line
If you have high homocysteine, folic acid treatment can help lower it and improve blood vessel function, but your genetic makeup may influence how well it works. Gram Research analysis suggests that genetic testing for MTHFR C677T could help predict your individual response. If you have the TT genotype, you may need higher doses, more frequent monitoring, or alternative treatments. Discuss genetic testing with your doctor to personalize your treatment plan. This recommendation has moderate confidence because the study is solid but represents one research group’s findings.
People with elevated homocysteine who are considering or currently taking folic acid supplements should care about these findings. Patients with a family history of heart disease or stroke may particularly benefit from understanding their genetic response to folic acid. Healthcare providers treating cardiovascular disease should consider these results when deciding on folic acid dosing and follow-up strategies. People of all ethnic backgrounds should be aware that genetic variations affect medication response, though this study’s population may not represent all groups equally.
Based on this study, you can expect to see improvements in homocysteine levels within 2 to 4 months of starting folic acid treatment. Blood vessel function improvements also appear within this timeframe. However, reaching your target homocysteine level may take up to 12 months, and the timeline depends on your genetic type. If you have the TT genotype, reaching targets may take longer or require dose adjustments. Discuss realistic timelines with your doctor based on your individual genetic profile.
Frequently Asked Questions
Does my MTHFR gene affect how well folic acid works for me?
Yes, research shows your MTHFR gene type significantly influences folic acid effectiveness. People with the CC version respond best, while those with the TT version have much lower success rates. Genetic testing can help predict your individual response and guide treatment decisions.
What is homocysteine and why does it matter for heart health?
Homocysteine is an amino acid in your blood that, when elevated, damages blood vessel walls and increases heart disease risk. Folic acid supplements help lower homocysteine levels, but how well they work depends partly on your genes. This study found that genetic differences affect both homocysteine reduction and blood vessel improvement.
If I have the TT MTHFR gene, should I take a higher dose of folic acid?
This study suggests TT patients may need different treatment approaches, but it doesn’t specify optimal doses. Discuss your genetic results with your doctor, who can determine whether a higher dose, a different supplement form, or alternative treatment would work better for you based on your individual situation.
How long does it take to see improvements from folic acid treatment?
This study found improvements in homocysteine levels and blood vessel function within 2 to 4 months, with continued improvement over 12 months. However, reaching your target homocysteine level may take longer, especially if you have the CT or TT gene version. Your doctor can give you a personalized timeline.
Should everyone with high homocysteine get genetic testing for MTHFR?
This research suggests genetic testing could help personalize folic acid treatment, but it’s not yet standard practice. Discuss with your doctor whether MTHFR testing makes sense for your situation, especially if standard folic acid treatment isn’t working well for you.
Want to Apply This Research?
- Track your homocysteine levels every 2 to 4 months if you’re taking folic acid for high homocysteine. Record the date, your homocysteine value, your folic acid dose, and any side effects. Note whether you’ve had genetic testing and your MTHFR genotype if available. This creates a personal record to share with your doctor and helps identify patterns in your response to treatment.
- If your genetic testing shows you have the CT or TT genotype, work with your doctor to optimize your folic acid dose or consider alternative treatments. Take your folic acid supplement consistently at the same time each day. Maintain a heart-healthy diet rich in leafy greens, legumes, and fortified grains, which provide natural folate. Track your adherence to the supplement regimen in the app to ensure you’re taking it as prescribed.
- Set up quarterly reminders to log your homocysteine test results in the app. Create a trend chart to visualize whether your levels are decreasing over time. If you reach your target homocysteine level, continue monitoring every 6 months to ensure levels stay controlled. If you’re not reaching targets after 6 months, flag this in the app as a discussion point with your doctor about dose adjustment or genetic testing.
This article summarizes research findings and should not replace professional medical advice. High homocysteine and cardiovascular disease are serious conditions requiring medical supervision. Do not start, stop, or change folic acid supplements without consulting your healthcare provider. Genetic testing for MTHFR should only be ordered and interpreted by a qualified healthcare professional. Individual responses to folic acid vary, and treatment plans should be personalized based on your complete medical history, current medications, and genetic profile. This research represents one study and should be considered alongside other evidence and your doctor’s clinical judgment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.